Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer

Strahlentherapie und Onkologie

Volumn 190, Issue 3, 2014, Pages 250-255

  Budach, V ^a   Becker, E T ^a   Boehmer, D ^a   Badakhshi, H ^a   Jahn, U ^a   Wernecke, K D ^a   Stromberger, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 Fluorouracil; Acute toxicity; Carcinoma; Head and neck neoplasms; Squamous cell; Treatment outcome

Indexed keywords

CISPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DESQUAMATION; DISTANT METASTASIS; DYSGEUSIA; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; LEUKOPENIA; MALE; METASTASIS FREE SURVIVAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIATION INJURIES;

EID: 84896370836     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0481-4     Document Type: Article

References (28)

1. Pignon JP, Maitre A le, Bourhis J (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69:112-114
2. Pignon JP, Maitre A le, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14
3. Blanchard P, Baujat B, Holostenco V et al (2011) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 100:33-40
4. Sadat F, Wienke A, Dunst J, Kuhnt T (2012) Survival of patients with head and neck cancer. Impact of physical status and comorbidities. Strahlenther Onkol 188:62-70
5. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23:1125-1135 (Pubitemid 46202268)
6. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
7. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
8. Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666-670
9. Kubes J, Cvek J, Vondracek V et al (2011) Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks): an alternative in the treatment of locally advanced head and neck cancer. Strahlenther Onkol 187:651-655
10. Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13:145-153
11. Loimu V, Collan J, Vaalavirta L et al (2011) Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin. Radiother Oncol 98:34-37
12. Alongi F, Bignardi M, Garassino I et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188:49-55
13. Jensen AD, Krauss J, Potthoff K et al (2012) Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial. Radiat Oncol 7:57
14. Abramyuk A, Appold S, Zophel K et al (2013) Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol 189:197-201
15. Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843-854 (Pubitemid 44292807)
16. Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28
17. Huguenin P, Beer KT, Allal A et al (2004) Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin On col 22:4665-4673
18. Jeremic B, Shibamoto Y, Milicic B et al (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458-1464 (Pubitemid 30205391)
19. Ghadjar P, Simcock M, Studer G et al (2012) Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys 82:524-531
20. Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804 (Pubitemid 28277960)
21. Bensadoun RJ, Benezery K, Dassonville O et al (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64:983-994
22. Semrau S, Waldfahrer F, Lell M et al (2010) Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradiotherapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol 187:15-22
23. Blanchard P, Bourhis J, Lacas B et al (2013) Taxane-cisplatin- fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31:2854-2860
24. Lee YJ, Lee CG, Cho BC et al (2010) Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Head Neck 32:235-243
25. Rampino M, Ricardi U, Munoz F et al (2011) Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol 23:134-140
26. Tsan DL, Lin CY, Kang CJ et al (2012) The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 7:215
27. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35
28. Budach V, Cho CC, Sedlmaier B et al (2012) Five years' results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. ASCO Annual Meeting Proceedings. J Clin Oncol supp 30(15 supp):5521